Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive
General Info
Coverage type
Country
Time period covered
January, 2019 - December, 2020
Data type
Scientific literature
Keywords
Citation
Journal
Diabetes Obes Metab
Pages
991-999
Publication year
2022
Suggested citation
Gao B, Gao W, Wan H, Xu F, Zhou R, Zhang X, Ji Q. Efficacy and safety of alogliptin versus acarbose in Chinese type 2 diabetes patients with high cardiovascular risk or coronary heart disease treated with aspirin and inadequately controlled with metformin monotherapy or drug-naive. Diabetes Obes Metab. 2022; 24(6): 991-999.